ZVRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zevra Therapeutics Inc (ZVRA) is not a strong buy at this moment for a beginner investor with a long-term focus. While the company has positive catalysts such as strong analyst ratings and potential growth opportunities, the technical indicators and insider selling trends suggest caution. Additionally, the financial performance shows a mixed picture with revenue growth but significant drops in net income and EPS. For now, holding off on buying is recommended until clearer positive signals emerge.
The MACD histogram is negative and contracting (-0.0813), indicating bearish momentum. RSI is neutral at 44.63, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 9.076) but below the pivot (9.721), suggesting limited upward momentum in the short term.
Analyst ratings are consistently positive with price targets significantly above the current price ($23-$26). Potential catalysts include Miplyffa's continued market penetration, EU approval, and patent term extensions. Revenue growth of 183.36% YoY in Q4 2025 is also a positive sign.
Insiders are selling heavily, with an 809.12% increase in selling activity over the last month. Net income and EPS have dropped significantly (-133.10% and -129.85% YoY, respectively), raising concerns about profitability. Technical indicators do not show strong bullish momentum.
In Q4 2025, revenue increased by 183.36% YoY to $34.13M, showing strong top-line growth. However, net income dropped by -133.10% YoY to $11.83M, and EPS fell by -129.85% YoY to 0.2, indicating profitability challenges. Gross margin improved to 94.62%, up 25.76% YoY.
Analysts are bullish on ZVRA, with multiple Buy ratings and price targets ranging from $23 to $26. Analysts highlight strong growth potential for Miplyffa and other pipeline opportunities, suggesting significant upside potential.
